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Summary
Introduction. In the last decades, visceral Leishmaniasis infec-
tion rate has increased in Western Mediterranean areas. Epide-
miological data show that in Italy, especially in some regions, 
the prevalence of canine form is high. The aim of this study is 
to evaluate the epidemiological setting of Leishmaniasis in Italy, 
according to age groups and geographical areas, and to estimate 
the associated direct medical costs.
Methods. The study examined the ordinary and day-hospital 
discharges and the respective mean of hospital length of stay 
for Leishmaniasis and visceral Leishmaniasis in Italy, during the 
period 1999-2003. Moreover, we collected data about notifica-
tions of Leishmaniasis, from 1993 to 2004, and mortality due to 
this infectious disease, from 1993 to 1998.
We evaluated the prevalence rates of discharges, the visceral and 
cutaneous Leishmaniasis notifications incidence rates and the 
mortality rates from disease, per 1,000,000 residents.
Costs analysis was performed getting DRG number 423 rate, 
which corresponds to “other diagnosis related to infectious and 
parasitary diseases”.
Results. Ordinary discharges decreased in the study period, 
while day-hospital discharges increased. Sicilia, Campania and 
Lazio regions showed the highest number of ordinary hospital 
discharges for Leishmaniasis (prevalence rates were respec-
tively 16.29, 15.02 and 12.83 per 1,000,000 residents, in 2003). 
Campania and Sicilia showed also the highest prevalence rates 
of day-hospital discharges (respectively 17.29 and 35.39 per 
1,000,000 residents in 2003).
The analysis of incidence rates of notifications showed a cyclic 
trend of the visceral form of the disease, with the highest rates 
observed in the group aged 0-14 years (incidence rates per 
1,000,000: 7.46 in 1996 and 8.59 in 2000).
The highest mortality rates were observed in the group aged over 
65 years; low but constant mortality rates for Leishmaniasis were 
seen in the age group 25-64 years.
Direct costs for both ordinary and day-hospital admissions were: 
1,561,218.46 € in 1999; 1,637,256.44 € in 2000; 1,459,892.92 
€ in 2001, 1,468,983.58 € in 2002 and 1,370,227.80 € in 
2003.
Discussion. Discharges for Leishmaniasis showed non-homoge-
neous trend in Italy, especially in coastal Regions. Leishmaniasis 
notifications have slowly increased after 1993 and a high number 
of notifications was observed in the 0-14 years old group.
The highest mortality rates were reported in the extreme age-
groups: mortality was relevant for patients over 65 years.
Moreover, cost analysis showed that health care of human Leish-
maniasis requires long time of hospitalization with consequent 
high costs.
Conclusion. Preventive measures have to be turned to extreme 
age groups. For future studies issues such as high costs of 
treating disease, cost-effectiveness evaluation of the current 
therapeutic approach compared to preventive interventions on 
dogs and vector insects would be of interest.
Introduction
human Leishmaniasis represents a serious public health 
concern in Mediterranean countries [1]. in italy, the ca-
nine form of this infectious disease is highly prevalent 
and is endemic in many areas, especially in central-
Southern regions where the prevalence of canine Leish-
maniasis ranges from 1,7% to 48,4% [2]. in recent years 
active foci of canine Leishmaniasis have been even 
identified in northern regions which were considered 
free from this concern until 1983 [3, 4].
Since 1993, the prevalence of the human form of the 
disease has increased [5] and the World health orga-
nization (Who) has identified visceral Leishmaniasis 
as an emerging zoonosis in Southern europe [3]. The 
disease is endemic in 88 countries; 90% of visceral 
Leishmaniasis occurs in Bangladesh, Brazil, india, 
Sudan and nepal, while 90% of cutaneous form 
occurs in Afghanistan, Algeria, Brazil, iran, Peru, 
Saudi Arabia and Syria. Globally speaking, there 
are 12 million cases worldwide and over 350 million 
people are at risk of infection [6]. The incidence rate 
of Leishmaniasis is of 1.5-2 million of cases per year 
worldwide, but the disease is greatly under-reported, 
as notification is compulsory in only 32 of 88 endemic 
countries. So, about 50% of new cases are recorded 
each year [6, 7]. in 2001, Who estimated 60,000 dea-
ths due to Leishmaniasis [5].
dogs represent the main cause of disease spreading, 
since they are the only domestic reservoir of the in-
fection [2, 3, 8]. epidemiologically, we distinguish 
two different patterns of transmission: the zoonotic 
form of the disease (in the Mediterranean countries), 
with the dog as the main source of infection, and the 
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anthroponotic one (in east Africa, Bangladesh, india, 
nepal), with man to man transmission [9].
epidemiological data showed that treating this disea-
se has been a challenge in some italian regions such 
as campania, Sicilia and Lazio, as the prevalence of 
canine Leishmaniasis in these regions is higher than 
in others [10].
in italy, there are two forms of Leishmaniasis: visceral 
and cutaneous. The visceral form can affect people of any 
age, mainly children, and it is characterized by irregular 
fever, weight loss, swelling of liver and spleen and anae-
mia; it can be mortal if untreated [11, 12]. The cutaneous 
form is characterized by single self-solving lesion or mul-
tiple lesions and tends to become chronic [11, 12].
children age, poor nutrition and professional status 
could predispose individuals to symptomatic Leish-
maniasis [12]. The severity of symptoms is strictly 
connected with the host immunological state, as well 
as the timeliness of diagnosis and treatment which 
improves disease prognosis.
The prevention of human Leishmaniasis cannot exclu-
de interventions of veterinary surgeons [11], as the 
canine form is endemic in many areas.
in italy, timely epidemiological studies have been 
carried out in single areas [13-15]. Sicilia represents a 
high risk geographic area and disease cases are increa-
sing among people as well as among dogs [13, 16]. 
Many studies focused on the role of phlebotomists 
and their distribution in italy [17]. After the Second 
World War the incidence rates of the disease were 
stable (10-20 cases per person-year), but, in recent 
years, Leishmaniasis seems to be re-emerged [5]; in 
2000, the incident cases were 200 [6]. The spreading 
of the disease in italy can be related to the setting of 
surveillance programs in some regions such as cam-
pania, Sicilia and Lazio, to the diffusion of new foci 
of canine Leishmaniasis and to the hiV/Leishmaniasis 
co-infection in humans.
in italy, Leishmaniasis affects mainly immunological-
compromised subjects, especially intra-venous drug 
users [6]. hiV/Leishmaniasis co-infection is highly 
represented in South-Western europe: about 85% of 
the first cases notified to Who until 1998, have been 
reported in these area [18]. italy, France, Portugal and 
Spain are countries with the highest number of hiV/
Leishmaniasis co-infections [19].
While hiV/Leishmaniasis co-infection is increasing 
in eastern Africa and the indian subcontinent, due 
to the simultaneous spread and geographical overlap 
of both diseases, cases of co-infection are expected 
to reduce in South-Western europe, as treatment 
(hAArT) is easily available. however, the number 
reported to Who continues to rise and it is maybe due 
to the increased awareness and better case definition 
of disease [9].
Moreover, recent studies show that the co-infection 
Leishmaniasis-hiV could be mortal [20-22] and this 
could represent a further public health problem.
Objective
The aim of our study was to analyse the epidemiologi-
cal setting of Leishmaniasis in italy, according to geo-
graphical areas and age groups.
We evaluated the number and the prevalence rates of 
ordinary and day-hospital discharges for Leishmaniasis 
and Visceral Leishmaniasis, according to geographical 
areas; we considered the mean length of stay in hospital 
for the disease and we studied the mortality for human 
Leishmaniasis in italy, according to age.
in order to have a full view of this concern, we also 
analysed the number of official notifications.
Moreover, we calculated direct hospitals costs, in order 
to assess the economic weight of the human form of the 
disease.
Methods
Using the Ministry of Health’s website [23], we acces-
sed hospital discharge data and the mean length of stay, 
due to Leishmaniasis (code icd9–cM*: 085), in italian 
hospitals and health care structures, from 1999 to 2003. 
We evaluated discharge data from both ordinary hospi-
talizations and day-hospitals and stratified our data by 
region of residence. We also evaluated the same data for 
visceral Leishmaniasis only (code icd9–cM*: 0850), 
according to region of residence and age groups (0-14; 
15-24; 25-64; > 65). We based the number of disease 
cases on discharge data.
The number of cutaneous and visceral Leishmaniasis 
notifications was obtained from the Ministry of Health’s 
website [24], for the period 1993-2004. resident popu-
lation was estimated using data from demo-istat [25] (at 
1st of January for each year) during the same period. We 
obtained population data both for region of residence 
and age groups (0-14; 15-24; 25-64; ≥ 65). Mortality 
data were derived from the “Archive of mortality for 
every single cause” of epicentro website [26], from 
1993 to 1998; we considered deaths from visceral and 
undetermined Leishmaniasis.
We evaluated the prevalence rates of Leishmaniasis 
cases (icd9: 085) and we calculated the percentage and 
the prevalence rates of visceral forms (icd9: 0850). The 
prevalence rates were calculated dividing the number of 
cases (based on discharge data) by resident population.
We estimated the incidence rates of visceral and cuta-
neous Leishmaniasis notifications and the mortality rates 
from Leishmaniasis. The incidence rates were computed 
as described for prevalence rates; the prevalence and the 
incidence rates were calculated for 1,000,000 residents.
costs analysis was performed getting the drG rates 
of ordinary hospitalization and one day/daily hospita-
lization for “other diagnosis related to infectious and 
parasitary diseases” (drG 423); from the Ministerial 
decree 30 June 1997 [27], they resulted 3,343.54 € and 
329.50 € respectively for ordinary and day-hospital di-
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scharges. We multiplied the rate values of ordinary and 
day-hospital hospitalizations for the respective number 
of discharges and we added the ordinary hospital costs to 
day-hospital ones to estimate total direct medical costs.
Results
Table i shows the number of ordinary and day-hospital 
discharged patients with the main diagnosis of Leishma-
niasis and the mean length of stay in hospital (in days) 
for the disease, in different italian regions, from 1999 
to 2003. The percentage of discharged patients with 
diagnosis of visceral Leishmaniasis and respective mean 
length of stay in hospital are shown in Table ii. dischar-
ges data were lacking for a lot of regions and were not 
reported for Trentino-Alto Adige.
Total ordinary hospital discharges were 449 in 1999 and 
370 in 2003, while day-hospital discharges were 182 in 
1999 and 404 in 2003.
The mean length of stay in hospital (in ordinary hospi-
talization) was 10.76 days in 1999 and 12.97 in 2003. 
The number of mean accesses to day-hospital was 4.68 
in 1999 and 4.84 in 2003 but it reached higher values 
within the study period (5.71 in 2001). in this period 
there was a decrease of the mean length of stay in 
hospital (in ordinary hospital) in Toscana, Lazio and 
calabria, while in Sardegna, Sicilia and Piemonte there 
was an important increase.
in the studied quinquennium, Sicilia, campania and 
Lazio presented the highest number of ordinary hospital 
discharges for Leishmaniasis (prevalence rates were re-
spectively 16.29, 15.02 and 12.83 for 1,000,000 residen-
ts, in 2003) (Tab. iii). Moreover campania and Sicilia 
showed also the highest prevalence rates of day-hospital 
discharges (17.29 and 35.39 for 1,000,000 residents in 
2003). regions with climate conditions which support 
vectors’ survival and replication showed differences in 
Leishmaniasis discharges and prevalence data: i.e. emi-
lia romagna presented low discharges prevalence rates, 
while Lazio, a region with similar climate of emilia 
romagna, showed higher values.
in Table iV the distribution of visceral Leishmaniasis 
discharges and corresponding mean length of stay in 
hospital is shown, stratified by age and gender. it is pos-
sible to note that the most affected groups were children 
from 1 to 4 years and adults from 25 to 64 years.
From 1993 to 2004, the temporal trend of Leishmania-
sis notifications incidence rates was analysed, both for 
total population and stratified for age groups (Fig. 1). 
The analysis showed a cyclic trend of the Visceral form 
of the disease, with inter-epidemic periods of about 
5 years, with peaks in the years 1995/1996, 2000 and 
2004, for all age groups. The highest incidence rates 
were observed for the group aged 0-14 years (incidence 
rates for 1,000,000: 7.46 in 1996; 8.59 in 2000; 7.45 in 
2004); people ≥ 65 years were less affected. Incidence 
rates for cutaneous Leishmaniasis notifications were hi-
gher in the age group from 0 to 14 years; incidence rates 
increased in all age groups in more recent years.
Leishmaniasis mortality rates stratified by age groups, 
in the years 1993-1998, showed that the group presen-
ting the highest values was the oldest one (≥ 65 years 
old), and the highest rates were observed in 1993 and 
1994 (0.33 dead individuals for 1,000,000 residents), 
followed by the age group 0-14 years which presen-
ted the highest rate in 1996 (0.12 dead individuals for 
1.000.000 residents). The age group 25-64 years showed 
low, but constant, mortality rates through the years.
direct hospitalizations costs, used as a proxy of the 
economic weight of Leishmaniasis (both the visceral 
and the cutaneous form) resulted higher in Sicilia, 
campania and Lazio (Tab. V) than in other regions; this 
was confirmed both for ordinary admissions and day-
hospital ones. in the studied quinquennium, total direct 
medical costs were respectively: 1,561,218.46 € in 
1999; 1,637,256.44 € in 2000; 1,459,892.92 € in 2001, 
1,468,983.58 € in 2002 and 1,370,227.80 € in 2003.
Discussion
our study shows that the number of cases of Leishma-
niasis presents non-homogeneous trend in italy, espe-
cially in coastal regions, through the study period.
The prevalence rates, based on discharges data, were 
higher in central-Southern regions and in islands (en-
demic area) than in other areas, where only sporadic 
cases were reported from 1999 to 2003. Probably such 
a phenomenon was not due to different climate condi-
tions, because some areas present similar conditions, 
such as emilia romagna and Lazio, showed different 
prevalence rates.
ordinary admissions decreased through the considered 
period, while day-hospital ones increased significantly. 
This suggests a better employ of resources, but it also 
demonstrates a constant and high health care need for 
this infectious disease.
campania and Sicilia showed the highest number of ca-
ses, both for day-hospital and ordinary hospitalization. 
however, we have to consider that these regions have 
set disease surveillance programs in recent years [3].
Visceral Leishmaniasis was responsible of about 60-70% 
of disease cases. The mean hospital stay did not increase 
through the whole period. From 1999 to 2003, the most 
affected age-groups were children from 1 to 4 years and 
adults from 25 to 64 of age. This fact was confirmed by the 
high number of notifications of visceral Leishmaniasis in 
the 0-14 age group, followed by the 25-64 age group, in 
the same period. The high number of notifications in the 
age-group from 25 to 64 can be related, in the most struck 
areas, with professional risk factors for Leishmaniasis or 
self-immunity diseases [28, 29], while the high number 
of cases among 0-14 years old individuals can be related 
to outdoor activities of children and adolescents.
our study confirms that human Leishmaniasis and, in 
particular, visceral Leishmaniasis, is re-emerging. in 
fact, notifications of the disease have slowly increased 
after 1993; there is a new disease spreading in italy, as 
observed from other Authors [5]. This can be explained 
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even by the identifications of new active foci of canine 
Leishmaniasis in northern regions [3, 4]. Anyway, other 
concomitant factors could play an important role in the 
spread of the disease such as the climatic changes in italy 
and the changing of human behaviours towards animals.
death from Leishmaniasis is a rare event and few peo-
ple died of Leishmaniasis in italy, from 1993 to 1998. 
Mortality was not relevant for most of patients, except 
for the elderly. it is interesting that the highest mortali-
ty rates were observed in the extreme age-group: these 
patients are the less exposed to risk factors, but they 
are the ones with the heaviest outcomes of the illness, 
maybe due to late diagnosis. Patients aged 1-14 years 
reached a top of mortality only in one year, while the 
group from 15 to 24 years showed a mortality rates 
equal to zero throughout the considered period. These 
data suggest that even if death represents a rare outco-
me of Leishmaniasis, the young and the elderly have 
to be considered at high risk for death. As the disease 
is fatal if untreated, priority will be given to early 
detection of human cases. in fact, several cases are 
undiagnosed or misdiagnosed, especially when people 
have difficult access to health services. early case fin-
ding [32] and immediate treatment of infected subjects 
are two important tools to limit the disease burden. 
diagnosis of Leishmaniasis lean on serological tests 
and on aspirates of spleen, bone marrow or lymph-no-
de. Both these two diagnostic approaches present some 
limits as the serological tests are too much centralized 
and parasitological exams are invasive and difficult to 
decentralise [33].
The diffusion of Leishmaniasis has to be faced through 
different interventions. it is known that environmental inter-
ventions of primary prevention (the struggle against vector 
insects, the control of canine and human reserves [28, 30]) 
are efficacious. in Public health, the control of Leishma-
niasis rests on preventive measures. The use of repulsive 
substances against phlebotomists, early diagnosis throu-
gh periodical veterinary dogs’ checkups and, above all, 
the engagement and the steadfastness to apply therapeu-
tic protocol [30] as treatment of dogs allow to reduce the 
parasite-concentration of the animals and to support the 
cells-mediated immune reply [31].
Moreover first line drugs (Sb5+) are too much expensi-
ve and they have to be given systematically for a long 
time. during recent years a lot of efforts have been 
made by researchers in human and veterinary medicine 
to develop new therapeutic protocols to treat Leishma-
niasis. despite of this, anti- Leishmaniasis drugs are still 
not efficient, cheap, and easy to administer to patients 
and lacking in side effects.
From our point of view the disease control can be 
obtained only by establishing a national surveillance 
system, implementation of already existing surveillance 
program and inviting physicians to look for the disease 
in patients with systemic symptoms.
Tab. III. Prevalence rates (per 1.000.000 residents) of ordinary hospitalization and day-hospital for leishmaniasis, stratified by regions, 
from 1999 to 2003.
 1999 2000 2001 2002 2003
Regions OH DH OH DH OH DH OH DH OH DH
 prev.  prev.  prev.  prev.  prev.  prev.  prev.  prev.  prev.  prev. 
 rates rates rates rates rates rates rates rates rates rates
Piemonte 1.89 1.18 2.60 2.37 3.55 2.13 1.19 0.95 1.18 1.89
lombardia 3.24 1.34 2.79 3.34 1.67 3.89 2.55 3.54 1.65 2.09
P.A. Bolzano 2.19 n.A. n.A. n.A. n.A. n.A. n.A. n.A. n.A. n.A.
P.A. trento 6.42 n.A. n.A. 4.25 6.32 2.11 2.09 n.A. 8.28 4.14
veneto 1.12 0.67 2.90 0.67 1.33 0.67 1.32 1.10 1.53 1.31
friuli v.g. 0.85 n.A. 0.85 n.A. 0.85 n.A. n.A. n.A. n.A. n.A.
liguria 7.51 1.88 5.04 3.78 12.03 6.97 6.37 1.91 11.45 5.72
emilia romagna 1.78 1.53 1.77 2.03 0.50 3.03 1.25 2.01 3.23 3.72
toscana 3.72 2.01 4.01 2.86 2.58 1.72 6.01 1.72 5.69 1.99
umbria 1.22 n.A. 3.65 n.A. 3.64 1.21 1.21 1.21 n.A. 1.20
Marche 1.38 0.69 0.69 n.A. n.A. 0.68 n.A. 0.68 1.35 n.A.
lazio 9.37 2.73 13.88 4.69 12.12 4.50 7.23 2.93 12.83 6.22
Abruzzo 3.97 1.59 3.96 2.38 3.96 0.79 3.96 n.A. 3.14 3.14
Molise 9.26 n.A. 3.10 n.A. 3.11 n.A. 9.36 n.A. 3.11 n.A.
campania 18.70 7.16 26.76 9.97 19.10 17.17 20.87 8.59 15.02 17.29
Puglia 7.42 0.74 8.68 2.97 10.18 2.98 7.21 1.49 6.21 1.24
calabria 7.35 4.41 5.92 4.44 6.44 4.46 8.96 7.46 4.98 4.98
sicilia 26.98 12.79 14.42 19.43 15.87 31.14 20.94 44.91 16.29 35.40
sardegna 14.62 7.31 15.26 12.21 8.56 7.95 6.74 6.13 7.33 4.89
Basilicata n.A. n.A. 6.65 n.A. 1.67 n.A. 6.69 1.67 1.68 5.03
valle d’Aosta n.A. n.A. n.A. n.A. n.A. 16.77 n.A. n.A. n.A. n.A.
total 7.89 3.20 8.10 5.11 6.99 6.88 7.05 6.65 6.45 7.05
dH = day-hospital discharges; od = ordinary hospital discharges; n.A. = not Available
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The implementation of surveillance system should be 
different in different areas in relation to the different 
distribution of disease, the different health services avai-
lable in the area and different perception of disease [28]. 
health education has to be supported in order to increase 
the level of awareness among exposed population and 
bring vectors and human resevoir under control trough 
promotion of control measures [34].
Primary prevention would be turned to reservoir con-
trol by using deltamethrin treated collars in dogs; these 
reduce up to 90% the proportion of sand flies that take 
a blood meal from dogs [35]. The reservoir control can 
be obtained only with the engage of veterinaries and 
Zooprophylactic institutes. The collaboration between 
medical and veterinary setting and the exchange of epi-
demiological data is the most important instrument to 
determine the priorities in the surveillance system and 
to control the spread of the disease.
regarding preventing measures direct to humans, our 
study shows that these should be turned to extreme age-
groups (young and elderly) which represent those at 
higher risk; further studies would be performed to probe 
the risk factors to be infected.
our study has some limitations and some strengths. one 
of the limits is represented by the possible information 
bias as the number of the notified cases of Leishma-
niasis may be underreported, even if the disease is 
included in the class two of notification, according to 
the Ministerial decree 15 december 1990. As disease 
is also under-diagnosed, so that not all cases have been 
hospitalized, we can hypothesize that we have under-
estimated disease burden. Moreover the costs analysis 
is not complete because we only considered the direct 
hospitalisation costs.
Anyway, we considered two different, institutional 
and reliable sources of data and we can so affirm 
that our study best represents italian situation. cost 
analysis, even if incomplete, shows that efforts would 
be done to improve and optimize treatment costs and 
times.
Fig. 1. italian temporal trend of visceral (fig. 1A) and cutaneous (fig. 1B) leishmaniasis notifications incidence rates (rate between notifi-
cations and population *1,000,000), for age-bands, from 1993 to 2004.
ePideMiology And direct MedicAl costs of HuMAn leisHMAniAsis in itAly
35
Ta
b
. V
. H
o
sp
it
al
iz
at
io
n
s 
co
st
s 
fo
r 
le
is
h
m
an
ia
si
s 
(in
 e
u
ro
), 
st
ra
ti
fi
ed
 b
y 
r
eg
io
n
s 
(1
99
9-
20
03
). 
o
rd
in
ar
y 
h
o
sp
it
al
iz
at
io
n
 (o
H
), 
d
ay
 h
o
sp
it
al
iz
at
io
n
 (d
H
) a
n
d
 t
o
ta
l c
o
st
s 
(t
o
ta
l =
 o
rd
in
ar
y 
+ 
d
ay
 h
o
sp
it
al
s 
co
-
st
s)
.
 
19
99
 
20
00
 
20
01
 
20
02
 
20
03
R
e
g
io
n
s 
D
H
 
O
H
 
To
ta
l 
D
H
 
O
H
 
To
ta
l 
D
H
 
O
H
 
To
ta
l 
D
H
 
O
H
 
To
ta
l 
D
H
 
O
H
 
To
ta
l
Pi
em
on
te
 
1,
64
7.
50
 
26
,7
48
.3
0 
28
,3
95
.8
0 
3,
29
5.
00
 
36
,7
78
.9
0 
40
,0
73
.9
0 
2,
96
5.
50
 
50
,1
53
.1
0 
53
,1
18
.6
0 
1,
31
8.
00
 
16
,7
17
.7
0 
18
,0
35
.7
0 
2,
63
6.
00
 
16
,7
17
.7
0 
19
,3
53
.7
0
lo
m
ba
rd
ia
 
3,
95
4.
00
 
96
,9
62
.7
0 
10
0,
91
6.
70
 
9,
88
5.
00
 
83
,5
88
.5
0 
93
,4
73
.5
0 
11
,5
32
.5
0 
50
,1
53
.1
0 
61
,6
85
.6
0 
10
,5
44
.0
0 
76
,9
01
.4
0 
87
,4
45
.4
0 
6,
26
0.
50
 
50
,1
53
.1
0 
56
,4
13
.6
0
P.
A.
 B
ol
za
no
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
—
 
—
 
—
 
—
 
—
 
—
 
—
 
0.
00
 
—
 
—
 
—
P.
A.
 t
re
nt
o 
—
 
10
,0
30
.6
0 
10
,0
30
.6
0 
65
9.
00
 
—
 
65
9.
00
 
32
9.
50
 
10
,0
30
.6
0 
10
,3
60
.1
0 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
65
9.
00
 
13
,3
74
.2
0 
14
,0
33
.2
0
ve
ne
to
 
98
8.
50
 
16
,7
17
.7
0 
17
,7
06
.2
0 
98
8.
50
 
43
,4
66
.0
0 
44
,4
54
.5
0 
98
8.
50
 
20
,0
61
.2
0 
21
,0
49
.7
0 
1,
64
7.
50
 
20
,0
61
.2
0 
21
,7
08
.7
0 
1,
97
7.
00
 
23
,4
04
.8
0 
25
,3
81
.8
0
fr
iu
li 
v.
g.
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
—
 
0.
00
 
—
 
—
 
—
li
gu
ria
 
98
8.
50
 
40
,1
22
.5
0 
41
,1
11
.0
0 
1,
97
7.
00
 
26
,7
48
.3
0 
28
,7
25
.3
0 
3,
62
4.
50
 
63
,5
27
.3
0 
67
,1
51
.8
0 
98
8.
50
 
33
,4
35
.4
0 
34
,4
23
.9
0 
2,
96
5.
50
 
60
,1
83
.7
0 
63
,1
49
.2
0
em
ili
a 
 
1,
97
7.
00
 
23
,4
04
.8
0 
25
,3
81
.8
0 
2,
63
6.
00
 
23
,4
04
.8
0 
26
,0
40
.8
0 
3,
95
4.
00
 
6,
68
7.
10
 
10
,6
41
.1
0 
2,
63
6.
00
 
16
,7
17
.7
0 
19
,3
53
.7
0 
4,
94
2.
50
 
43
,4
66
.0
0 
48
,4
08
.5
0
ro
m
ag
na
to
sc
an
a 
2,
30
6.
50
 
43
,4
66
.0
0 
45
,7
72
.5
0 
3,
29
5.
00
 
46
,8
09
.6
0 
50
,1
04
.6
0 
1,
97
7.
00
 
30
,0
91
.9
0 
32
,0
68
.9
0 
1,
97
7.
00
 
70
,2
14
.3
0 
72
,1
91
.3
0 
2,
30
6.
50
 
66
,8
70
.8
0 
69
,1
77
.3
0
u
m
br
ia
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
10
,0
30
.6
0 
10
,0
30
.6
0 
32
9.
50
 
10
,0
30
.6
0 
10
,3
60
.1
0 
32
9.
50
 
3,
34
3.
50
 
3,
67
3.
00
 
32
9.
50
 
—
 
32
9.
50
M
ar
ch
e 
32
9.
50
 
6,
68
7.
10
 
7,
01
6.
60
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
32
9.
50
 
—
 
32
9.
50
 
32
9.
50
 
—
 
32
9.
50
 
—
 
6,
68
7.
10
 
6,
68
7.
10
la
zi
o 
4,
61
3.
00
 
16
0,
48
9.
90
 
16
5,
10
2.
90
 
7,
90
8.
00
 
23
7,
39
1.
30
 
24
5,
29
9.
30
 
7,
57
8.
50
 
20
7,
29
9.
50
 
21
4,
87
8.
00
 
4,
94
2.
50
 
12
3,
71
1.
00
 
12
8,
65
3.
50
 
10
,5
44
.0
0 
22
0,
67
3.
60
 
23
1,
21
7.
60
Ab
ru
zz
o 
65
9.
00
 
16
,7
17
.7
0 
17
,3
76
.7
0 
98
8.
50
 
16
,7
17
.7
0 
17
,7
06
.2
0 
32
9.
50
 
16
,7
17
.7
0 
17
,0
47
.2
0 
—
 
16
,7
17
.7
0 
16
,7
17
.7
0 
1,
31
8.
00
 
13
,3
74
.2
0 
14
,6
92
.2
0
M
ol
is
e 
—
 
10
,0
30
.6
0 
10
,0
30
.6
0 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
—
 
10
,0
30
.6
0 
10
,0
30
.6
0 
—
 
3,
34
3.
50
 
3,
34
3.
50
ca
m
pa
ni
a 
13
,5
09
.5
0 
35
7,
75
8.
80
 
37
1,
26
8.
30
 
18
,7
81
.5
0 
51
1,
56
1.
60
 
53
0,
34
3.
10
 
32
,2
91
.0
0 
36
4,
44
5.
90
 
39
6,
73
6.
90
 
16
,1
45
.5
0 
39
7,
88
1.
30
 
41
4,
02
6.
80
 
32
,6
20
.5
0 
28
7,
54
4.
40
 
32
0,
16
4.
90
Pu
gl
ia
 
98
8.
50
 
10
0,
30
6.
20
 
10
1,
29
4.
70
 
3,
95
4.
00
 
11
7,
02
3.
90
 
12
0,
97
7.
90
 
3,
95
4.
00
 
13
7,
08
5.
10
 
14
1,
03
9.
10
 
1,
97
7.
00
 
96
,9
62
.7
0 
98
,9
39
.7
0 
1,
64
7.
50
 
83
,5
88
.5
0 
85
,2
36
.0
0
ca
la
br
ia
 
2,
96
5.
50
 
50
,1
53
.1
0 
53
,1
18
.6
0 
2,
96
5.
50
 
40
,1
22
.5
0 
43
,0
88
.0
0 
2,
96
5.
50
 
43
,4
66
.0
0 
46
,4
31
.5
0 
4,
94
2.
50
 
60
,1
83
.7
0 
65
,1
26
.2
0 
3,
29
5.
00
 
33
,4
35
.4
0 
36
,7
30
.4
0
si
ci
lia
 
21
,0
88
.0
0 
45
1,
37
7.
90
 
47
2,
46
5.
90
 
31
,9
61
.5
0 
24
0,
73
4.
90
 
27
2,
69
6.
40
 
51
,0
72
.5
0 
26
4,
13
9.
70
 
31
5,
21
2.
20
 
73
,4
78
.5
0 
34
7,
72
8.
20
 
42
1,
20
6.
70
 
57
,9
92
.0
0 
27
0,
82
6.
70
 
32
8,
81
8.
70
sa
rd
eg
na
 
3,
95
4.
00
 
80
,2
45
.0
0 
84
,1
99
.0
0 
6,
59
0.
00
 
83
,5
88
.5
0 
90
,1
78
.5
0 
4,
28
3.
50
 
46
,8
09
.6
0 
51
,0
93
.1
0 
3,
29
5.
00
 
36
,7
78
.9
0 
40
,0
73
.9
0 
2,
63
6.
00
 
40
,1
22
.5
0 
42
,7
58
.5
0
Ba
si
lic
at
a 
—
 
—
 
—
 
—
 
13
,3
74
.2
0 
13
,3
74
.2
0 
—
 
3,
34
3.
50
 
3,
34
3.
50
 
32
9.
50
 
13
,3
74
.2
0 
13
,7
03
.7
0 
98
8.
50
 
3,
34
3.
50
 
4,
33
2.
00
va
lle
 
—
 
—
 
—
 
—
 
—
 
—
 
65
9.
00
 
—
 
65
9.
00
 
—
 
—
 
—
 
—
 
—
 
—
d’
Ao
st
a
to
ta
l 
59
,9
69
.0
0 
1,
50
1,
24
9.
50
 
1,
56
1,
21
8.
50
 
95
,8
84
.5
0 
1,
54
1,
37
1.
90
 
1,
63
7,
25
6.
40
 
12
9,
16
4.
00
 
1,
33
0,
72
8.
90
 
1,
45
9,
89
2.
90
 
12
4,
88
0.
50
 
1,
34
4,
10
3.
10
 
1,
46
8,
98
3.
60
 
13
3,
11
8.
00
 
1.
23
7.
10
9,
80
 
1,
37
0,
22
7.
80
A. MAnnocci et Al.
36
Lack of an effective vaccine against different form of 
Leishmaniasis and the difficulty to contrast the diffusion 
of vectors represent the major limits for the control of 
the disease.
As the high economic weight of the disease, cost-ef-
fectiveness evaluation of current therapeutic approach 
compared to preventive interventions toward dogs and 
vector insects would be interesting for future studies.
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